

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0151US1	Application No. 10/550,934
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Masayuki Tsuchiya et al.	
		Filing Date August 25, 2006	Group Art Unit 1643

(37 CFR §1.98(b))

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	5,789,554	08/1998	Leung <i>et al.</i>			
	2	5,837,242	11/1998	Holliger <i>et al.</i>			
	3	5,840,344	11/1998	Fukushima			
	4	5,885,574	03/1999	Elliott			
	5	6,126,980	10/2000	Smith <i>et al.</i>			
	6	6,579,692	06/2003	Fukushima			
	7	6,719,972	04/2004	Gribben <i>et al.</i>			
	8	6,759,043	07/2004	Fukushima			
	9	7,456,260	11/2008	Rybak <i>et al.</i>			
	10	2003/0147894	08/2003	Fukushima <i>et al.</i>			
	11	2003/0157100	08/2003	Fukushima <i>et al.</i>			
	12	2003/0157577	08/2003	Fukushima <i>et al.</i>			
	13	2003/0211108	11/2003	Fukushima <i>et al.</i>			
	14	2004/0073013	04/2004	Fukushima <i>et al.</i>			
	15	2009/0022687	01/2009	Matsumoto <i>et al.</i>			
	16	2009/0028854	01/2009	Igawa <i>et al.</i>			
	17	2009/0117097	05/2009	Igawa <i>et al.</i>			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	18	EP 0 721 015	07/10/1996	Europe				
	19	EP 1 035 132	09/13/2000	Europe				
	20	EP 1 327 681	07/16/2003	Europe				
	21	EP 1 396 500	03/10/2004	Europe				
	22	EP 1 262 548	08/10/2008	Europe				
	23	JP 7236475	09/12/1995	Japan			Abstract only	
	24	JP 11-092500	04/06/1999	Japan			Abstract only	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0151US1	Application No. 10/550,934
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Masayuki Tsuchiya et al.	
		Filing Date August 25, 2006	Group Art Unit 1643

(37 CFR §1.98(b))

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Design ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	25	JP 2000-95800	04/04/2000	Japan			Abstract only	
	26	WO 91/16928	11/14/1991	WIPO				
	27	WO 92/19759	11/12/1992	WIPO			English abstract	
	28	WO 94/13806	06/23/1994	WIPO				
	29	WO 96/36360	11/21/1996	WIPO				
	30	WO 97/01633	01/16/1997	WIPO				
	31	WO 97/32601	09/12/1997	WIPO			English abstract	
	32	WO 98/44001	08/10/1998	WIPO				
	33	WO 99/17364	04/08/1999	WIPO				
	34	WO 00/53634	09/14/2000	WIPO			English abstract	
	35	WO 00/75191	12/14/2000	WIPO				
	36	WO 01/77342	10/18/2001	WIPO				
	37	WO 01/87337	11/22/2001	WIPO				
	38	WO 02/097033	12/05/2002	WIPO				
	39	WO 02/094880	11/28/2002	WIPO			English abstract	

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Design ID	Document
	40	AVENT et al., "Monoclonal antibodies that recognize different membrane proteins that are deficient in Rhnull human erythrocytes. One group of antibodies reacts with a variety of cells and tissues whereas the other group is erythroid-specific," <i>Biochem. J.</i> , 251:499-505 (1988)
	41	BARTLEY et al., "Identification and Cloning of a Megakaryocyte Growth and Development Factor That is a Ligand for the Cytokine Receptor Mpl," <i>Cell</i> , 77:1117-1124 (1994)
	42	BAZIL et al., "Apoptosis of human hematopoietic progenitor cells induced by crosslinking of surface CD43, the major sialoglycoprotein of leukocytes," <i>Blood</i> , 86:502-511 (1995)
	43	BAZZONI et al., "Chimeric tumor necrosis factor receptors with constitutive signaling activity," <i>Proc. Natl. Acad. Sci. USA</i> , 92(12):5376-5580 (1995)
	44	BERESFORD et al., "Binding Characteristics and Tumor Targeting of a Covalently Linked Divalent CC49 Single-Chain Antibody," <i>Int. J. Cancer</i> , 81:911-917 (1999)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0151US1	Application No. 10/550,934
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Masayuki Tsuchiya et al.	
		Filing Date August 25, 2006	Group Art Unit 1643

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	45	BERGER et al., "Inhibition of intractable nucleases with ribonucleoside-vanadyl complexes: isolation of messenger ribonucleic acid from resting lymphocytes," <i>Biochemistry</i> , 18(23):5143-5149 (1979)
	46	BODMER et al., "TRAIL Receptor-2 Signals Apoptosis Through FADD and Caspase-8," <i>Nat. Cell Biol.</i> , 2:241-243 (2000)
	47	BOWIE et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <i>Science</i> , 247:1306-1310 (1990)
	48	BROWN et al., "Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins," <i>J. Cell Biology</i> , 111(6 Pt 1):2785-2794 (1990)
	49	BROWN et al., "Integrin-associated protein (CD47) and its ligands," <i>Trends Cell Biology</i> , 11(3):130-135 (2001)
	50	BUCHSBAUM et al., "Antitumor Efficacy of TRA-8 Anti-DR5 Monoclonal Antibody Alone or in Combination with Chemotherapy and/or Radiation Therapy in a Human Breast Cancer Model," <i>Clin. Cancer Res.</i> , 9:3731-3741 (2003)
	51	BURTHERM et al., "Hairy cell interactions with extracellular matrix: expression of specific integrin receptors and their role in the cell's response to specific adhesive proteins," <i>Blood</i> , 84(3):873-882 (1994)
	52	CALDAS et al., "Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen," <i>Mol. Immunol.</i> , 39:941-952 (2003)
	53	CARON et al., "Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies," <i>J. Exp. Med.</i> , 176:1191-1195 (1992)
	54	CHIEN et al., "Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism," <i>Proc. Nat. Acad. Sci. USA</i> , 86:5532-5536 (1989)
	55	CHIRGWIN et al., "Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease," <i>Biochemistry</i> , 18(24):5294-5299 (1979)
	56	CHUNTHARAPAI et al., "Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4," <i>J. Immunol.</i> , 166:4891-4898 (2001)
	57	COCHLOVIUS et al., "Cure of Burkitt's Lymphoma in Severe Combined Immunodeficiency Mice by T Cells, Tetraivalent CD3 x CD19 Tandem Diabody and CD28 Costimulation," <i>Cancer Res.</i> , 60:4336-4341 (2000)
	58	COOPER et al., "Transendothelial migration of neutrophils involves integrin-associated protein (CD47)," <i>Proc. Natl. Acad. Sci. USA</i> , 92:3978-3982 (1995)
	59	DANIEL et al., "Pathway of apoptosis induced in Jurkat T Lymphoblasts by anti-HLA Class I antibodies," <i>Human Immunology</i> , 65(3):189-199 (2004)
	60	DE LEON et al., "High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study," <i>BMC Cancer</i> , 9(48):1-9 (2009)
	61	DEGLI-ESPOSTI et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family," <i>J. Exp. Med.</i> , 186:1165-1170 (1997)
	62	DE SAUVAGE et al., "Stimulation of Megakaryocytopoiesis and Thrombopoiesis by the c-Mpl Ligand," <i>Nature</i> , 369:533-538 (1994)
	63	DESPLANCQ et al., "Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3," <i>Protein Engineering</i> , 7(8):1027-1033 (1994)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0151US1	Application No. 10/550,934
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Masayuki Tsuchiya et al.	
		Filing Date August 25, 2006	Group Art Unit 1643

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	64	DE ST. GROTH et al., "Production of Monoclonal Antibodies: Strategy and Tactics," <i>Journal of Immunological Methods</i> , 35:1-21 (1980)
	65	DILLMAN, "Monoclonal antibodies for treating cancer," <i>Ann. Int. Med.</i> , 11(7):592-603 (1989)
	66	DORAI et al., "Mammalian cell expression of single-chain Fv (sFv) antibody proteins and their C-terminal fusions with interleukin-2 and other effector domains," <i>Biotechnology</i> , 12(9):890-897 (1994)
	67	EMERY et al., "Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL," <i>J. Biol. Chem.</i> , 273: 14363-14367 (1998)
	68	FELGENHAUER et al., "Nucleotide Sequences of the cDNAs Encoding the V-Regions of H- and L-Chains of a Human Monoclonal Antibody Specific to HIV-1 - gp41," <i>Nucleic Acids Research</i> , 18(16):4927 (1990)
	69	FUJIMOTO et al., "50-kD integrin-associated protein does not detectably influence several functions of glycoprotein IIb-IIIa complex in human platelets," <i>Blood</i> , 86(6):2174-2182 (1995)
	70	FUKUSHIMA et al., "Enhanced hematopoiesis in vivo and in vitro by splenic stromal cells derived from the mouse with recombinant granulocyte colony-stimulating factor," <i>Blood</i> , 80(8):1914-1922 (1992)
	71	FUKUSHIMA et al., "Apoptosis of Bone Marrow Cells Via Integrin Associated Protein by the Novel Monoclonal Antibody," <i>Blood</i> , 94(10):479A (1999)
	72	GALFRE et al., "Preparation of monoclonal antibodies: strategies and procedures," <i>Methods in Enzymology</i> , 73:3-46 (1981)
	73	GALFRE et al., "Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG," <i>Nature</i> , 277:131-133 (1979)
	74	GIUSTI et al., "Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region," <i>Proc. Natl. Acad. Sci. USA</i> , 84:2926-2930 (1987)
	75	GODING, "Monoclonal Antibodies: Principles and Practice," <i>Academic Press</i> , second Ed., 125:129 (1986)
	76	GREENSPAN et al., "Defining epitopes: It's not as easy as it seems," <i>Nature Biotechnology</i> , 17:936-937 (1999)
	77	GRELL et al., "TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytotoxicity," <i>Lymphokine and Cytokine Research</i> , 12(3):143-148 (1993)
	78	GRIFFITH et al., "Functional Analysis of TRAIL Receptors Using Monoclonal Antibodies," <i>J. Immunol.</i> , 162:2597-2605 (1999)
	79	GÜSSOW and SEEMANN, "Humanization of Monoclonal Antibodies," <i>Methods in Enzymology</i> , 203:99-121 (1991)
	80	HOLLIGER et al., "Specific Killing of Lymphoma Cells by Cytotoxic T-Cells Mediated by a Bispecific Diabody," <i>Protein Engineering</i> , 9(3):299-305 (1996)
	81	HOPP et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification," <i>Biotechnology</i> , 6:1204-1210 (1988)
	82	HORAN et al., "Dimerization of the extracellular domain of granulocyte-colony stimulating factor receptor by ligand binding: a monovalent ligand induces 2:2 complexes," <i>Biochemistry</i> , 35:4886-4896 (1996)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0151US1	Application No. 10/550,934
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Masayuki Tsuchiya et al.	
		Filing Date August 25, 2006	Group Art Unit 1643

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	83	HUSTON et al., "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in <i>Escherichia Coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> , 85:5879-5883 (1988)
	84	ITO et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," <i>Cell</i> , 66:233-243 (1991)
	85	JIANG et al., "A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2," <i>J. Biol. Chem.</i> , 280(6):4656-4662 (2005)
	86	JONES et al., "Rapid PCR-Cloning of Full-Length Mouse Immunoglobulin Variable Regions," <i>Biotechnology</i> , 9:88-89 (1991)
	87	KEARNEY, et al., "A New Mouse Myeloma Cell Line That Has Lost immunoglobulin Expression But Permits The Construction of Antibody-Secreting Hybrid Cells Lines," <i>The Journal of Immunology</i> , 123(4):1548-1550 (1979)
	88	KEEN et al., "The use of serum-free medium for the production of functionally active humanized monoclonal antibody from NSO mouse myeloma cells engineered using glutamine synthetase as a selectable marker," <i>Cytotechnology</i> , 18(3):207-217 (Abstract) (1994)
	89	KIPRIYANOV et al., "Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells," <i>In. J. Cancer</i> , 77:763-772 (1998)
	90	KOHLER, et al., "Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion," <i>Eur. J. Immunol.</i> , 6:511-519 (1976)
	91	KORTT et al., "Recombinant anti-sialidase single-chain variable fragment antibody: Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex," <i>Eur. J. Biochem.</i> , 221:151-157 (1994)
	92	KORTT et al., "Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten- residue linkers form dimmers and with zero-residue linker a trimer," <i>Protein Engineering</i> , 10(4):423-433 (1997)
	93	KOZAK, M., "At Least Six Nucleotides Preceding the AUG Initiator Codon Enhance Translation in Mammalian Cells," <i>J. Mol. Biol.</i> , 196:947-950 (1987)
	94	LARRICK, et al., "Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes From Single Hybridoma Cells," <i>Biotechnology</i> , 7:934-938 (1989)
	95	LAW et al., "Observations On The Effect Of A Folic-Acid Antagonist On Transplantable Lymphoid Leukemias In Mice," <i>Journal of the National Cancer Institute</i> , 10:179-193 (1949)
	96	LEI et al., "Characterization of the <i>Erwinia Carotovora pelB</i> Gene and Its Product Pectate Lyase," <i>Journal of Bacteriology</i> , 4379-4383 (1987)
	97	LIN et al., "Structure-function relationships in glucagon: properties of highly purified des-His-1-, monoiodo-, and (des-Asn-28, Thr-29)(homoserine lactone-27)-glucagon," <i>Biochemistry</i> , 14:1559-1563 (1975)
	98	LINDBERG et al., "Molecular Cloning of Integrin-Associated Protein: An Immunoglobulin Family Member with Multiple Membrane-Spanning Domains Implicated in $\alpha_v\beta_3$ -Dependent Ligand Binding," <i>The Journal of Cell Biology</i> , 123(2):485-496, The Rockefeller University Press (1993)
	99	LINDBERG et al., "Rh-Related Antigen CD47 is the Signal-Transducer Integrin-Associated Protein," <i>J. Biol. Chem.</i> , 269:1567-1570 (1994)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0151US1	Application No. 10/550,934
		Information Disclosure Statement by Applicant (Use several sheets if necessary)	
		Applicant Masayuki Tsuchiya et al.	
		Filing Date August 25, 2006	Group Art Unit 1643

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	100	MARGULIES et al., "Somatic Cell Hybridization of Mouse Myeloma Cells," <i>Cell</i> , 8:405-415 (1976)
	101	MARIUZZA et al., "The structural basis of antigen-antibody recognition," <i>Annu. Rev. Biophys. Biophys. Chem.</i> , 16:139-159 (1987)
	102	MARSTERS et al., "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain," <i>Curr. Biol.</i> , 7:1003-1006 (1997)
	103	MATEO et al., "Induction of Apoptosis in B-Cells From Chronic Lymphocytic Leukemia (B-CLLs) by CD47," <i>FASEB Journal</i> , 12(5):A1082 (1998)
	104	MAWBY et al., "Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumor marker OA3," <i>Biochem. J.</i> , 304:525-530 (1994)
	105	METHIA et al., "Oligodeoxynucleotides Antisense to the Proto-Oncogene <i>c-Mpl</i> Specifically Inhibit In Vitro Megakaryocytopoiesis," <i>Blood</i> , 82(5):1395-1401 (1993)
	106	MILLI et al., "The VDJ Repertoire Expressed in Human preB Cells Reflects the Selection of <i>Bona Fide</i> Heavy Chains," <i>Eur. J. Immunol.</i> , 26:63-69 (1996)
	107	MIZUSHIMA et al., "pEF-BOS, a Powerful Mammalian Expression Vector," <i>Nucleic Acids Research</i> , 18(17):5322 (1990)
	108	MOORE et al., "Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor," <i>Biochemistry</i> , 38:13960-13967 (1999)
	109	MORI et al., "Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2," <i>Cell Death and Differentiation</i> , 11:203-207 (2004)
	110	MULLIGAN et al., "Synthesis of Rabbit B-Globin in Cultured Monkey Kidney Cells Following Infection with a SV40 B-Globin Recombinant Genome," <i>Nature</i> , 277:108-114 (1979)
	111	NAKAYAMA et al., "Thrombocytosis in preterm infants: a possible involvement of thrombopoietin receptor gene expression," <i>Journal of Molecular Medicine</i> , 83:316-320 (2005)
	112	NGO et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz, Jr. et al. Editors, Birkhauser Boston, 433-506 (1994)
	113	O'BRIEN et al., "Monoclonal antibodies for the human insulin receptor stimulate intrinsic receptor-kinase activity," <i>Biochim. Soc. Trans.</i> , 14(6):1021-1023 (1986)
	114	OHTSUKA et al., "Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway," <i>Oncogene</i> , 22:2034-2044 (2003)
	115	PAN et al., "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL," <i>Science</i> , 277:815-818 (1997)
	116	PAN et al., "The Receptor for the Cytotoxic Ligand TRAIL," <i>Science</i> , 276:111-113 (1997)
	117	PAUL, <i>Fundamental Immunology</i> , Raven Press, NY, Chapter 8, p. 242 (1993)
	118	PETTERSON et al., "CD47 Signals T Cell Death," <i>J. Immunol.</i> , 703:1-7040 (1999)
	119	PETTERSON, "CD47 and death signaling in the immune system," <i>Apoptosis</i> , 5:299-306 (2000)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0151US1	Application No. 10/550,934
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Masayuki Tsuchiya et al.	
		Filing Date August 25, 2006	Group Art Unit 1643

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	120	REINHOLD et al., "In vivo expression of alternatively spliced forms of integrin-associated protein (CD47)," <i>J. Cell Science</i> , 108:3419-3425 (1995)
	121	RIECHMANN et al., "Reshaping Human Antibodies for Therapy," <i>Nature</i> , 332:323-327 (1988)
	122	REITER et al., "Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv," <i>Protein Engineering</i> , 7(5):697-704 (1994)
	123	REITER et al., "Stabilization of the Fv Fragments in Recombinant Immunotoxins by Disulfide Bonds Engineered into Conserved Framework Regions," <i>Biochemistry</i> , 33:5451-5459 (1994)
	124	ROUE et al., "Mitochondrial dysfunction in CD47-mediated caspase-independent cell death: ROS production in the absence of cytochrome c and AIF release," <i>Biochimie</i> , 85:741-746 (2003)
	125	ROZSNYAY et al., "Phenylarsine oxide (PAO) blocks antigen receptor-induced calcium response and tyrosine phosphorylation of a distinct group of proteins," <i>Immunology Lett.</i> , 37(2-3):197-205 (1993)
	126	SATO et al., "Reshaping a Human Antibody to Inhibit the Interleukin 6-Dependent Tumor Cell Growth," <i>Cancer Research</i> , 53:851-856 (1993)
	127	SCHICKEL, et al., "Gene for Integrin-Associated Protein (IAP, CD47): Physical Mapping, Genomic Structure, and Expression Studies in Skeletal Muscle," <i>Biochem. Cell Biol.</i> , 80(2):169-176 (2002)
	128	SCHWARTZ et al., "A superactive insulin: [B10-aspartic acid]insulin(human)," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 84:6408-6411 (1987)
	129	SCHWARTZ et al., "A 50-kDa Integrin-associated Protein Is Required for Integrin-regulated Calcium Entry in endothelial Cells," <i>J. Biol. Chem.</i> , 268(27):19931-19934 (1993)
	130	SCHMIDT et al., "A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGf receptor," <i>Int. J. Cancer</i> , 65(4):538-546 (1996)
	131	SHERIDAN et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors," <i>Science</i> , 277:818-821 (1997)
	132	SHIGETA et al., "Sperm-immobilizing monoclonal antibody to human seminal plasma antigens," <i>Clin. Exp. Immunol.</i> , 42:458-462 (1980)
	133	SHULMAN et al., "A better cell line for making hybridomas secreting specific antibodies," <i>Nature</i> , 276:269-270 (1978)
	134	SOUYRI, M., "Mpl: from an acute myeloproliferative virus to the isolation of the long sought thrombopoietin," <i>Seminars in Hematology</i> , 35(3):222-231 (1998)
	135	SPAARGAREN et al., "Antibody-induced Dimerization Activates the Epidermal Growth Factor Receptor Tyrosine Kinase," <i>The J. Biol. Chem.</i> , 266(3):1733-1739 (1991)
	136	STANCOVSKI et al., "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth," <i>Proc. Natl. Acad. Sci. USA</i> , 88:8691-8695 (1991)
	137	TROWBRIDGE, I.S., "Interspecies Spleen-Myeloma Hybrid Producing Monoclonal Antibodies Against Mouse Lymphocyte Surface Glycoprotein, T200," <i>J. Exp. Med.</i> , 148:313-323 (1978)
	138	VAN GEELEN et al., "Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines," <i>Br. J. Cancer</i> , 89(2):363-373 (2003)
	139	VERMA et al., "Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems," <i>Journal of Immunological Methods</i> , 216:165-181 (1998)
	140	WALCZAK et al., "TRAIL-R2: A Novel Apoptosis-Mediating Receptor for TRAIL," <i>EMBO J.</i> , 16:5386-5397 (1997)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0151US1	Application No. 10/550,934
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Masayuki Tsuchiya et al.	
		Filing Date August 25, 2006	Group Art Unit 1643

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	141	WELLS, "Perspectives in Biochemistry," <i>Biochemistry</i> , 29(37):8509-8517 (1990)
	142	WILEY et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis," <i>Immunity</i> , 3:673-682 (1995)
	143	WINKLER et al., "Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody," <i>J. Immunol.</i> , 265:4505-4514 (2000)
	144	XIE et al., "Direct Demonstration of MuSK Involvement in Acetylcholine Receptor Clustering Through Identification of Agonist ScFv," <i>Nature Biotechnology</i> , 15(8):768-771 (1997)
	145	YANABU et al., "Tyrosine phosphorylation and p72syk activation by an anti-glycoprotein Ib monoclonal antibody," <i>Blood</i> , 89(5):1590-1598 (1997)
	146	YARDEN et al., "Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation," <i>Biochemistry</i> , 26(5):1434-1442 (1987)
	147	YELTON et al., "Fusion of Mouse Myeloma and Spleen Cells," <i>Current Topics in Microbiology and Immunology</i> , 81:1-7 (1978)
	148	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/530,696, mailed October 19, 2006, 8 pages
	149	FISH & RICHARDSON P.C., Response to Restriction Requirement dated October 19, 2006, in U.S. App. Ser. No. 10/530,696, filed November 16, 2006, 1 page
	150	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed December 21, 2006, 19 pages
	151	FISH & RICHARDSON P.C., Amendment in Reply to Office Action dated December 21, 2006 in U.S. App. Ser. No. 10/530,696, filed April 23, 2007, 16 pages
	152	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/530,696, mailed August 8, 2007, 13 pages
	153	U.S. EXAMINER ANNE GUSSOW, USPTO Interview Summary in U.S. App. Ser. No. 10/530,696, mailed November 26, 2007, 3 pages
	154	FISH & RICHARDSON P.C., Amendment in Reply to Office Action dated August 8, 2007 in U.S. App. Ser. No. 10/530,696, filed December 6, 2007, 12 pages
	155	U.S. EXAMINER ANNE GUSSOW, USPTO Advisory Action in U.S. App. Ser. No. 10/530,696, mailed December 14, 2007, 4 pages
	156	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed February 5, 2008, 9 pages
	157	FISH & RICHARDSON, Amendment in Reply to Office Action dated February 5, 2008 in U.S. App. Ser. No. 10/530,696, filed August 5, 2008, 7 pages
	158	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed November 17, 2008, 18 pages
	159	FISH & RICHARDSON, Amendment in Reply to Office Action dated November 17, 2008 in U.S. App. Ser. No. 10/530,696, filed February 17, 2009, 14 pages
	160	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 10/530,696, mailed June 8, 2009, 10 pages
	161	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2003/013063, mailed November 18, 2003, 2 pages
	162	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2003/013063, dated February 6, 2004, 4 pages

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0151US1	Application No. 10/550,934
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Masayuki Tsuchiya et al.	
		Filing Date August 25, 2006	Group Art Unit 1643

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	163	EPO EXAMINER W. BERNHARDT, European Search Report for App. Ser. No. EP 03 75 1456, dated April 4, 2006, 2 pages
	164	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Restriction Requirement in U.S. App. Ser. No. 10/548,727, mailed April 12, 2007, 6 pages
	165	FISH & RICHARDSON P.C., Reply to Restriction Requirement dated April 12, 2007 in U.S. App. Ser. No. 10/548,727, filed May 3, 2007, 1 page
	166	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/548,727, mailed August 3, 2007, 21 pages
	167	FISH & RICHARDSON P.C., Reply to Office Action dated August 3, 2007 in U.S. App. Ser. No. 10/548,727, filed January 15, 2008, 15 pages
	168	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Final Office Action in U.S. App. Ser. No. 10/548,727, mailed April 29, 2008, 23 pages
	169	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Advisory Action in U.S. App. Ser. No. 10/548,727, mailed September 24, 2008, 6 pages
	170	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/548,727, mailed January 28, 2009, 16 pages
	171	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/003334, mailed June 15, 2004, 3 pages
	172	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/003334, dated May 2, 2005, 6 pages
	173	U.S. EXAMINER LORRAINE SPECTOR, USPTO Restriction Requirement in U.S. App. Ser. No. 10/551,504, mailed June 27, 2008, 6 pages
	174	FISH & RICHARDSON P.C., Response to Restriction Requirement dated June 27, 2008 in U.S. App. Ser. No. 10/551,504, filed September 29, 2008, 13 pages
	175	U.S. EXAMINER LORRAINE SPECTOR, USPTO Restriction Requirement in U.S. App. Ser. No. 10/551,504, mailed December 16, 2008, 5 pages
	176	FISH & RICHARDSON P.C., Response to Restriction Requirement dated December 16, 2008 in U.S. App. Ser. No. 10/551,504, filed December 23, 2008, 14 pages
	177	U.S. EXAMINER LORRAINE SPECTOR, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/551,504, mailed April 15, 2009, 35 pages
	178	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018506, mailed March 22, 2005, 3 pages
	179	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018506, 8 pages
	180	EPO EXAMINER ROBERT RANKIN, European Search Report for App. Ser. No. EP 04 82 0316, dated July 17, 2008, 3 pages
	181	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018499, mailed January 18, 2005, 2 pages
	182	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018499, dated January 26, 2006, 5 pages
	183	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,413, mailed January 4, 2008, 8 pages

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0151US1	Application No. 10/550,934
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Masayuki Tsuchiya et al.	
		Filing Date August 25, 2006	Group Art Unit 1643

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	184	FISH & RICHARDSON P.C., Response to Restriction Requirement dated January 4, 2008 in U.S. App. Ser. No. 10/582,413, filed February 4, 2008, 2 pages
	185	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,413, mailed March 31, 2008, 17 pages
	186	FISH & RICHARDSON P.C., Amendment in Reply to Action dated March 31, 2008 in U.S. App. Ser. No. 10/582,413, filed June 30, 2008, 20 pages
	187	U.S. EXAMINER ANNE GUSSOW, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed June 30, 2008, 2 pages
	188	U.S. EXAMINER BRADLEY DUFFY, USPTO Notice of Informal or Non-Responsive Amendment in U.S. App. Ser. No. 10/582,413, mailed October 20, 2008, 3 pages
	189	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed November 12, 2008, 4 pages
	190	FISH & RICHARDSON P.C., Amendment in Reply to Notice of Informal or Non-Responsive Amendment dated October 20, 2008 in U.S. App. Ser. No. 10/582,413, filed November 17, 2008, 10 pages
	191	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed November 25, 2008, 4 pages
	192	U.S. EXAMINER BRADLEY DUFFY, USPTO Interview Summary in U.S. App. Ser. No. 10/582,413, mailed December 24, 2008, 4 pages
	193	U.S. EXAMINER BRADLEY DUFFY, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,413, mailed March 11, 2009, 8 pages
	194	FISH & RICHARDSON P.C., Response to Restriction Requirement dated March 11, 2009 in U.S. App. Ser. No. 10/582,413, filed April 8, 2009, 8 pages
	195	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018493, mailed March 22, 2005, 2 pages
	196	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018493, dated December 20, 2005, 7 pages
	197	EPO EXAMINER INGE KALSNER, European Search Report for App. Ser. No. EP 04 82 0305, dated October 6, 2008, 3 pages
	198	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,304, mailed November 20, 2008, 7 pages
	199	FISH & RICHARDSON P.C., Response to Restriction Requirement dated November 20, 2008 in U.S. App. Ser. No. 10/582,304, filed December 16, 2008, 3 pages
	200	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,304, mailed April 1, 2009, 38 pages
	201	FISH & RICHARDSON P.C., Amendment in Reply to Office Action dated April 1, 2009 in U.S. App. Ser. No. 10/582,304, filed June 30, 2009, 15 pages
	202	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/018501, mailed March 29, 2005, 2 pages
	203	JAPANESE EXAMINER YOSHIKO KUWAHARA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/018501, dated November 4, 2005, 7 pages
	204	EPO EXAMINER HELENA DOMINGUES, European Search Report for App. Ser. No. EP 04 82 0311, dated January 28, 2009, 4 pages

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0151US1	Application No. 10/550,934
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Masayuki Tsuchiya et al.	
		Filing Date August 25, 2006	Group Art Unit 1643

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	205	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/005152, mailed July 20, 2004, 2 pages
	206	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/005152, dated February 14, 2005, 6 pages
	207	EPO EXAMINER WIEBKE BERNHARDT, European Search Report for App. Ser. No. EP 04 72 6750, dated February 4, 2008, 3 pages
	208	U.S. EXAMINER BRADLEY DUFFY, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/547,747, mailed June 1, 2009, 41 pages
	209	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2006/309890, mailed July 18, 2006, 2 pages
	210	JAPANESE EXAMINER MASASHI HONDA, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/309890, dated November 19, 2007, 5 pages
	211	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Restriction Requirement in U.S. App. Ser. No. 10/582,654, mailed May 26, 2009, 9 pages
	212	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Restriction Requirement in U.S. App. Ser. No. 10/399,518, mailed November 25, 2005, 9 pages
	213	FOLEY & LARDNER LLP, Response to Restriction Requirement dated November 25, 2005 in U.S. App. Ser. No. 10/399,518, filed December 23, 2005, 3 pages
	214	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed March 27, 2006, 38 pages
	215	FOLEY & LARDNER LLP, Amendment in Reply to Action dated March 27, 2006 in U.S. App. Ser. No. 10/399,518, filed September 26, 2006, 26 pages
	216	FOLEY & LARDNER LLP, Supplemental Amendment in Reply to Action dated March 27, 2006 in U.S. App. Ser. No. 10/399,518, filed October 11, 2006, 11 pages
	217	FOLEY & LARDNER LLP, Supplemental Amendment in Reply to Action dated March 27, 2006 in U.S. App. Ser. No. 10/399,518, filed October 13, 2006, 11 pages
	218	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed December 28, 2006, 29 pages
	219	FOLEY & LARDNER LLP, Amendment in Reply to Action dated December 28, 2006 in U.S. App. Ser. No. 10/399,518, filed May 3, 2007, 22 pages
	220	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. No. 10/399,518, mailed June 7, 2007, 13 pages
	221	FOLEY & LARDNER LLP, Amendment in Reply to Action dated June 7, 2007 in U.S. App. Ser. No. 10/399,518, filed September 7, 2007, 9 pages
	222	U.S. EXAMINER DAVID J. BLANCHARD, Advisory Action in U.S. App. Ser. No. 10/399,518, mailed September 27, 2007, 5 pages
	223	U.S. EXAMINER DAVID J. BLANCHARD, Interview Summary in U.S. App. Ser. No. 10/399,518, mailed November 13, 2007, 3 pages
	224	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed January 31, 2008, 14 pages
	225	FOLEY & LARDNER LLP, Amendment in Reply to Action dated January 31, 2008 in U.S. App. Ser. No. 10/399,518, filed April 30, 2008, 7 pages

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0151US1	Application No. 10/550,934
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Masayuki Tsuchiya et al.	
		Filing Date August 25, 2006	Group Art Unit 1643

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	226	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. No. 10/399,518, mailed August 4, 2008, 8 pages
	227	U.S. EXAMINER DAVID J. BLANCHARD, Advisory Action in U.S. App. Ser. No. 10/399,518, mailed November 7, 2008, 4 pages
	228	FOLEY & LARDNER LLP, Amendment in Reply to Action dated November 7, 2008 in U.S. App. Ser. No. 10/399,518, filed October 23, 2008, 8 pages
	229	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/399,518, mailed February 17, 2009, 12 pages
	230	FOLEY & LARDNER LLP, Amendment in Reply to Action dated February 17, 2009 in U.S. App. Ser. No. 10/399,518, filed May 18, 2009, 26 pages
	231	U.S. EXAMINER BRADLEY DUFFY, USPTO Final Office Action in U.S. App. Ser. No. 10/582,413, mailed June 25, 2009, 28 pages
	232	FISH & RICHARDSON P.C., Reply to Office Action dated January 28, 2009 in U.S. App. Ser. No. 10/548,727, filed June 26, 2009, 9 pages
	233	U.S. EXAMINER ELLY GERALD STOICA, USPTO Restriction Requirement in U.S. App. Ser. No. 11/913,229, mailed July 8, 2009, 6 pages
	234	FISH & RICHARDSON P.C., Response to Restriction Requirement dated July 8, 2009 in U.S. App. Ser. No. 11/913,229, filed August 4, 2009, 1 page
	235	EPO EXAMINER TERESA SOMMERFELD, European Search Report for App. Ser. No. EP 06 74 6578, dated June 25, 2009, 2 pages
	236	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2004/004696, mailed July 27, 2004, 5 pages
	237	JAPANESE PATENT OFFICE, International Preliminary Report on Patentability for App. Ser. No. PCT/JP2004/004696, dated February 9, 2005, 10 pages
	238	EPO EXAMINER N. FAVRE, European Search Report for App. Ser. No. EP 04 72 4770, dated March 31, 2006, 4 pages

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	